- Home
- ALTS vs QNCX Comparison
ALTS vs QNCX Comparison
Compare ALTS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- QNCX
- Stock Information
- Founded
- ALTS 1976
- QNCX 2012
- Country
- ALTS United States
- QNCX United States
- Employees
- ALTS N/A
- QNCX N/A
- Industry
- ALTS
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALTS
- QNCX Health Care
- Exchange
- ALTS NYSE
- QNCX Nasdaq
- Market Cap
- ALTS 125.5M
- QNCX 47.7M
- IPO Year
- ALTS N/A
- QNCX 2019
- Fundamental
- Price
- ALTS $7.45
- QNCX $1.93
- Analyst Decision
- ALTS
- QNCX Strong Buy
- Analyst Count
- ALTS 0
- QNCX 5
- Target Price
- ALTS N/A
- QNCX $8.00
- AVG Volume (30 Days)
- ALTS 304.5K
- QNCX 267.4K
- Earning Date
- ALTS 08-18-2025
- QNCX 08-12-2025
- Dividend Yield
- ALTS N/A
- QNCX N/A
- EPS Growth
- ALTS N/A
- QNCX N/A
- EPS
- ALTS N/A
- QNCX N/A
- Revenue
- ALTS $18,046,000.00
- QNCX N/A
- Revenue This Year
- ALTS $185.91
- QNCX N/A
- Revenue Next Year
- ALTS $64.93
- QNCX N/A
- P/E Ratio
- ALTS N/A
- QNCX N/A
- Revenue Growth
- ALTS N/A
- QNCX N/A
- 52 Week Low
- ALTS $1.29
- QNCX $0.51
- 52 Week High
- ALTS $10.95
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ALTS 49.44
- QNCX 64.07
- Support Level
- ALTS $6.60
- QNCX $1.65
- Resistance Level
- ALTS $8.12
- QNCX $1.83
- Average True Range (ATR)
- ALTS 0.79
- QNCX 0.15
- MACD
- ALTS -0.03
- QNCX 0.00
- Stochastic Oscillator
- ALTS 68.18
- QNCX 54.39
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. The company operates in three operating segments: Fintech: provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, Biotechnology: Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties; Corporate and Others: Corporate and Other segment consists of certain corporate general and administrative costs. Company has revenue from Fintech Segment.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.